Insitro operates at “the convergence of human biology and machine learning.” More specifically, it uses artificial intelligence to build models of various human illnesses, using those models to forecast previously unknown solutions beyond human intuition. These models use the power of ML to improve drug discovery and development. Founded by Daphne Koller, Insitro has drawn investment from an exhaustive array of VC and financial firms.
The company was founded in 2011 and is headquartered in San Francisco, California. It has raised over $100 million in funding from investors such as Salesforce Ventures, Lightspeed Venture Partners, and Sapphire Ventures.
Insitro’s mission is to deliver the world’s first continuous support experience (SX) platform that enables companies to understand and act on the voice of the customer in real-time. It uses natural language processing and machine learning to extract customer signals from business communications, such as case evaluation and agent coaching tools. It also provides recommendations to managers to get ahead of escalations and helps to identify the best cases in a backlog to review.
Insitro has been trusted by leading technology companies such as Salesforce, Nutanix, and Adobe. It has also helped them reduce their escalation rates, increase their agent productivity, and improve their customer satisfaction. Insitro is a leader in the field of AI-powered customer service analytics.